Last checked at 13 May 2022 12:43
FOR RELEASE ON | 13 May 2022 |
Director Declaration
IP Group plc (LSE: IPO) ("the Group"), which develops world-changing science and technology businesses across life sciences, technology and cleantech, confirms that Elaine Sullivan, a non-executive director of the Group, has been appointed as a director of Nykode Therapeutics AS. This disclosure is made in accordance with LR 9.6.14R of the Listing Rules.
For more information, please contact:
IP Group plc | www.ipgroupplc.com |
Angela Leach, Company SecretaryLiz Vaughan-Adams, Communications | +44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802 |
Notes for editors
About IP Group
IP Group develops world-changing science and technology businesses across life sciences, technology and cleantech. The Group has a strong track record of success, having been the founder investor in a number of high-profile companies including Oxford Nanopore Technologies plc, and has one of the most exciting portfolios of high-growth businesses in Europe. The Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs world-changing technologies emerging from the UK's leading universities and research institutions. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.
For more information, please visit our website at www.ipgroupplc.com.
ENDS